Land: Singapore
Språk: engelska
Källa: HSA (Health Sciences Authority)
GADOTERIC ACID
TRANSMEDIC PTE LTD
V08CA02
27.932 g/ 100 ml
INJECTION
GADOTERIC ACID 27.932 g/ 100 ml
INTRAVENOUS
Prescription Only
GUERBET
ACTIVE
1996-11-18
Läs hela dokumentet
IS1200SG02 (clean version) – based on CCSI ver. 4 & HSA requested wordings 1 DOTAREM ® 0.5 mmol/mL solution for injection in vials Gadoteric acid 1. NAME OF THE MEDICINAL PRODUCT Dotarem 0.5 mmol/mL, solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Per 100 mL of solution: Gadoteric acid* ........................................................................................................ 27.932 g corresponding to DOTA ................................................................................ 20.246 g corresponding to gadolinium oxide ................................................................. 9.062 g * Gadoteric acid: complex of gadolinium oxide with 1, 4, 7, 10 tetraazacyclododecane-N,N’,N’’,N’’’ tetraacetic acid (DOTA). Contrast agent concentration: ……………………………………………………………0.5 mmol/mL For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection in vials. Clear, colourless to pale yellow solution. Osmolality: 1350 mOsm.kg -1 Viscosity at 20°C: 3.2 mPa.s Viscosity at 37°C: 2.0 mPa.s pH: 6.5 to 8.0 4. CLINICAL PARTICULARS 4.1. Therapeutic indications This medicinal product is for diagnostic use only. Nuclear magnetic resonance imaging: Neuroradiology: tumour of the spine and the surrounding tissues, intracranial tumours. Abdominal radiology: primary and secondary tumours. Primary tumour of the bone and soft tissues. 4.2. Posology and method of administration Posology Adults The recommended dose is 0.1 mmol/kg, i.e. 0.2 mL/kg, in adults. Special populations Impaired renal function The adult dose applies to patients with mild to moderate renal impairment (GFR ≥ 30 ml/min/1.73m 2 ). Dotarem should only be used in patients with severe renal impairment (GFR < 30 ml/min/1.73m 2 ) and in patients in the perioperative liver transplantation period after careful risk/benefit assessment and if the diagnostic information is essential and not available with non-contrast enhanced MRI (see Läs hela dokumentet